Difference between revisions of "Part:BBa K4165197"
(→Dry lab) |
(→Dry lab) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 16: | Line 16: | ||
<p style=" font-weight: bold; font-size:14px;"> Modeling </p> | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | ||
The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model was obtained from Apptest. | The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model was obtained from Apptest. | ||
| + | |||
| + | |||
<html> | <html> | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/ab-36-42-model.png" style="margin-left:200px;" alt="" width="500" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/ab-36-42-model.png" style="margin-left:200px;" alt="" width="500" /></p> | ||
Latest revision as of 20:03, 11 October 2022
Amyloid beta peptide 17 (Aβ 36-42)
This part encodes a part of the Amyloid 𝛽 fragment (36-42) which has the ability to bind to A𝛽 plaques inside the brain.
Usage and Biology
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 36 to 42 of the fibril.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry lab
Modeling
The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model was obtained from Apptest.
Figure 1.: Amyloid-beta (36-42) top model visualized by Pymol.
References
1- Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.